Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Change in Interest Receivables (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Change in Interest Receivables data on record, last reported at $28000.0 in Q4 2020.

  • For Q4 2020, Change in Interest Receivables rose 165.12% year-over-year to $28000.0; the TTM value through Dec 2020 reached $188000.0, changed N/A, while the annual FY2024 figure was -$206000.0, 520.41% down from the prior year.
  • Change in Interest Receivables reached $28000.0 in Q4 2020 per KLRS's latest filing, down from $364000.0 in the prior quarter.
  • Across five years, Change in Interest Receivables topped out at $364000.0 in Q3 2020 and bottomed at -$253000.0 in Q2 2020.